Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable.

Johan BlakkisrudAyca LøndalenJostein DahleAnne Catrine MartinsenArne KolstadCaroline Stokke

Published in: Acta oncologica (Stockholm, Sweden) (2021)

Myelosuppression in the form of thrombocytopenia and neutropenia in patients treated with [177Lu]Lu-lilotomab satetraxetan can be predicted from the SPECT/CT-derived absorbed dose estimate to the red marrow.

Keyphrases

computed tomography
contrast enhanced
dual energy
pet ct